Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses

Taofeek K. Owonikoko, MD,a,* Huifeng Niu, PhD, b Kristiaan Nackaerts, MD, PhD, c Tibor Csoszi, MD, d Gyula Ostoros, MD, e Zsuzsanna Mark, MD, f Christina Baik, MD, MPH g Anil Abraham Joy, MD, h Christos Chouaid, MD, i Jesus Corral Jaime, MD, j Vitezslav Kolek, MD, PhD, k Margaretta Majem, MD, PhD, l Jaromir Roubec, MD, PhD, m Edgardo S. Santos, MD, FACCP, n Anne C. Chiang, MD, PhD, o Giovanna Speranza, MD, p Chandra P. Belani, MD, q Lauren Byers, MD, t Brittany Bahamon, BSc, b Cong Li, PhD, b Alberto Chiappori, MD, r Manish R. Patel, MD, s Krisztina Czebe, MD, t Emily Sheldon-Waniga, PhD, b Eric F. Kong, PhD, u Miguel Williams, MS, b Sunita Badola, MSc, b Hyunjin Shin, PhD, b Lisa Bedford, MSc, b Jeffrey A. Ecsedy, PhD, t Matthew Bryant, BSc, u Sian Jones, PhD, u

*Corresponding author.

Drs. Owonikoko and Niu equally contributed to this work.

Disclosure: Dr. Owonikoko reports grants and personal fees from Novartis, BMS, AstraZeneca, and Amgen; personal fees from Takeda, AbbVie, G1 Therapeutics, EMD Serono, and PharmAmar; and grants from Merck and United Therapeutics outside the submitted work. Dr. Niu reports employment by Millennium Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Dr. Nackaerts reports a grant from Millennium Pharmaceuticals (limited funding to institution). Dr. Baik reports fees from Novartis, Loxo, Pfizer, AstraZeneca, Celgene, Roche/Genentech, Merck Sharp and Dohme, MedImmune, Mirati, GlaxoSmithKline, Daiichi Sankyo, National Institutes of Health/National Cancer Institute, and Blueprint Medicines outside the submitted work; she also reports consultation for Novartis and AstraZeneca. Dr. Chouaid reports personal fees from AstraZeneca and AbbVie, as well as grants from Abbvie, Lilly, BMS and Amgen outside the submitted work. Dr. Santos reports speaker bureau service for Genentech, Lilly, Takeda, Celgene, Merck, Pfizer, AstraZeneca, and Boehringer Ingelheim. Dr. Chiang reports personal fees from AstraZeneca and AbbVie, as well as grants from Abbvie, Lilly, BMS and Amgen outside the submitted work. Dr. Chiappori reports personal fees from Boehringer Ingelheim, Lilly, AstraZeneca, and Pfizer; and receipt of research funds from Novartis, BMS, and AstraZeneca. Ms. Bahamon, Dr. Li, Mr. Williams, Ms. Badola, Dr. Shin, Ms. Bedford, and Ms. Leonard report employment by Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Ms. Byers reports current employment by MaxCyte, Inc., and previous employment by Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Dr. Byers reports clinical trial research funding and a preclinical (laboratory) research grant to her institution from Takeda, as well as personal fees from AstraZeneca, AbbVie, GenMab, BergenBio, PharmAmar, SA, Sierra Oncology, Bristol-Myers Squibb, Aletheia Therapeutics, Inc., and Merck. Dr. Spigel reports research grants from Acerta Pharma, Aeglea Biotherapeutics, ARMO Biosciences, Astellas Pharma, Celldex, Clovis Oncology, Daiichi Sankyo, G1 Therapeutics, GRAIL, Ipsen, Millennium, Neon Therapeutics, Oncogenex, Tesaro, Transgene, University of Texas Southwestern Medical Center - Simmons Cancer Center; research grants and travel/expense reimbursement from EMD Serono; consulting/advisory roles and research grants from Abbvie, Amgen, Foundation Medicine, GlaxoSmithKline, Nektar, Takeda; consulting/advisory roles, research grants and travel/expense reimbursement from AstraZeneca, Boehringer Ingelheim, Lilly, Merck, Pfizer; consulting/advisory roles for Evelo Therapeutics, Illumina, Moderna Therapeutics, PharmAmar, Precision Oncology, TRM Oncology; travel and expense reimbursement from Genzyme, Intuitive Surgical, Purdue Pharma, Spectrum Pharmaceuticals, and Sysmex, outside the submitted work. The remaining authors declare no conflict of interest.

Trial Registration: Phase 2 Study of Alisertib (MLN8237) in Combination with Paclitaxel versus Placebo in Combination with Paclitaxel as Second-Line Therapy for Small Cell Lung Cancer. NCT02038647.

Presented at the European Society for Medical Oncology 2016 Annual Congress, October 7–11, 2016, Copenhagen, Denmark; and the International Association for the Study of Lung Cancer 17th World Congress on Lung Cancer, December 4–7, 2016, Vienna, Austria.

Address for correspondence: Taofeek K. Owonikoko, MD, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, 1365 Clifton Rd., NE, Room C3080, Atlanta, GA, 30322.

E-mail: towonik@emory.edu

© 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

ISSN: 1556-0864

https://doi.org/10.1016/j.jtho.2019.10.013
ABSTRACT

Introduction: We assessed the Aurora A kinase inhibitor, alisertib, plus paclitaxel (henceforth referred to as alisertib/paclitaxel) as second-line treatment for SCLC.

Methods: In this double-blind study, patients with relapsed or refractory SCLC were stratified by relapse type (sensitive versus resistant or refractory) and brain metastases and randomized 1:1 to alisertib/paclitaxel or placebo plus paclitaxel (henceforth referred to as placebo/paclitaxel) in 28-day cycles. The primary endpoint was progression-free survival (PFS). Associations of c-Myc expression in tumor tissue (prespecified) and genetic alterations in circulating tumor DNA (retrospective) with clinical outcome were evaluated.

Results: A total of 178 patients were enrolled (89 in each arm). The median PFS was 3.32 months with alisertib/paclitaxel versus 2.17 months with placebo/paclitaxel (hazard ratio [HR] = 0.77, 95% confidence limit [CI]: 0.557–1.067, p = 0.113 in the intent-to-treat population versus HR = 0.71, 95% CI: 0.509–0.985, p = 0.038 with corrected analysis applied). Among 140 patients with genetic alterations, patients with cell cycle regulator mutations (cyclin-dependent kinase 6 gene [CDK6], retinoblastoma-like 1 gene [RBL1], retinoblastoma-like 2 gene [RBL2], and retinoblastoma 1 gene [RB1]) had significantly improved PFS with alisertib/paclitaxel versus with placebo/paclitaxel (3.68 versus 1.80 months, respectively [HR = 0.395, 95% CI: 0.239–0.654, p = 0.0003]), and overall survival (7.20 versus 4.47 months, respectively [HR = 0.427, 95% CI: 0.259–0.704, p = 0.00085]). A subset of patients with c-Myc expression showed significantly improved PFS with alisertib/paclitaxel. The incidence of grade 3 or higher drug-related adverse events was 67% (58 patients) with alisertib/paclitaxel versus 22% (25 patients) with placebo/paclitaxel. Twelve patients (14%) versus 11 (12%) died on study, including four versus zero treatment-related deaths.

Conclusions: Efficacy signals were seen with alisertib/paclitaxel in relapsed or refractory SCLC. c-Myc expression and mutations in cell cycle regulators may be potential predictive biomarkers of alisertib efficacy; further prospective validations are warranted.

Keywords: Phase II; Aurora A kinase; Alisertib; Paclitaxel; SCLC

Introduction

SCLC is an aggressive malignancy, accounting for 13% to 18% of all lung cancer diagnoses.1,2 For many
patients with SCLC, the outlook is bleak. In treated extensive-stage SCLC, the median overall survival (OS) is just 7 to 12 months.5,4 The prognosis for relapsed or refractory SCLC is more dismal, with a median OS of 4 to 5 months.5

There is a strong correlation between the efficacy of second-line therapy and the quality and duration of response (DOR) to initial treatment (sensitive versus resistant or refractory relapse).6 Response rates are particularly poor (≤10%) in patients with resistant or refractory disease who relapse 3 months or less from the end of initial therapy.5 Patients with platinum-sensitive disease (relapse >3 months from end of initial therapy) have a relatively better outcome (response rate ~25%).5

Because of poor responses to current treatments, there is a critical unmet medical need in patients with SCLC, thereby justifying efforts to evaluate novel targeted agents (with validated predictive biomarkers).7,8 One potential target is Aurora A kinase (AAK), a key regulator of mitosis.9 AAK is amplified or overexpressed in several solid tumors, including SCLC, and may play a role in tumorigenesis.10,11 Inhibition of AAK leads to disrupted mitosis and cell death, reduced proliferation, and induction of apoptosis in SCLC cells.10,12

Amplification of v-myc avian myelocytomatosis viral oncogene homolog gene (MYC) in SCLC cell lines is associated with improved sensitivity to Aurora kinase inhibitors.13,14 Amplification and overexpression of the MYC gene family occurs in 18% to 31% of SCLCs and is more common in chemorefractory disease.15 The gene product, c-Myc (a transcription factor), binds directly to AAK, and inhibition of this interaction by AAK inhibitors results in c-Myc degradation and cell death.16,17 Thus, the Myc–AAK protein complex represents an actionable drug target for AAK inhibitors.

Alisertib (MLN8237) is an investigational, selective, oral, small molecule AAK inhibitor that has been studied in various solid tumors and hematologic malignancies.18–23 Single-agent activity was demonstrated in a phase II study of patients with relapsed or refractory solid tumors, including SCLC (n = 48).23 In patients with SCLC, the objective response rate (ORR) was 21% and the median progression-free survival (PFS) was 2.1 months.23 On the basis of preclinical evidence of synergy, alisertib plus paclitaxel (henceforth referred to as alisertib/paclitaxel) was evaluated in patients with breast and ovarian cancer19 and showed promise over paclitaxel alone, with PFS and ORR trending in favor of the combination.19 Preclinical data have also shown alisertib/paclitaxel synergy in SCLC; increased antitumor activity with the combination versus with the single agents was demonstrated in xenograft tumor models derived from human SCLC cell lines and human SCLC primary tumors (Takeda, data on file). The preclinical and clinical data thus provided justification for this phase II study of alisertib/paclitaxel as second-line therapy for relapsed or refractory SCLC. As part of this study, analyses were undertaken to assess the impact of c-Myc protein expression and genetic alterations on clinical outcomes.

**Patients and Methods**

**Study Design**

This multicenter, randomized, double-blind, placebo-controlled phase II trial (NCT02038647) enrolled patients across 54 sites in the United States (19 sites), Canada (three sites), and Europe (32 sites) from May 7, 2014, to October 26, 2015. The trial was conducted in accordance with applicable regulatory requirements, International Conference on Harmonization Good Clinical Practice guidelines, and the ethical principles founded in the Declaration of Helsinki. Study documentation was approved by the institutional review board and/or independent ethics committee at each site. Patients provided written informed consent.

Patients were randomized 1:1 to receive either alisertib (40 mg by mouth twice daily for 3 weeks on days 1–3, 8–10, and 15–17) plus paclitaxel (60 mg/m² intravenously on days 1, 8, and 15) or placebo (by mouth twice daily as per alisertib) plus paclitaxel (80 mg/m² intravenously on days 1, 8, and 15) in 28-day cycles. The dosing schedule permitted maximal overlap of systemic exposures between alisertib and paclitaxel while providing sufficient treatment-free periods to allow recovery from toxicities associated with both agents. Randomization was stratified by type of relapse after primary treatment, based on the common definition for each type10 (with sensitive defined as relapsed >90 but <180 days after primary treatment and resistant or refractory defined as relapsed ≤90 days after primary treatment) and presence of brain metastases (yes versus no) at study entry. Patients received treatment until progressive disease, discontinuation because of toxicity, loss to follow-up, study termination, protocol violation, or patient withdrawal. The study team and site staff responsible for assessing patients were blinded to treatment assignment; participating sites were required to designate a non-blinded study pharmacist for dose preparations.

**Patients**

The study enrolled patients at least 18 years old with a pathologically (histologically or cytologically) confirmed diagnosis of SCLC. Patients were required to have progressed within 180 days of last platinum dose, after receiving a standard platinum-based chemotherapy
regimen as first-line treatment, and to have measurable
disease per the Response Evaluation Criteria in Solid
Tumors version 1.1 within 2 weeks before randomiza-
tion. Other key inclusion and exclusion criteria can be
found in the Supplementary Methods.

**End Points and Assessments**

The primary end point was PFS (time from random-
ization to progressive disease or death), with patients
stratified by type of relapse after primary treatment
(sensitive versus resistant or refractory disease) and
presence of brain metastases. PFS was also analyzed in
patient subgroups according to baseline characteristics.
Secondary end points were safety and/or tolerability, OS,
ORR including complete response, disease control rate
(DCR: complete response, partial response, or stable
disease ≥8 weeks), and DOR. Exploratory end points
included correlative biomarker studies to evaluate the
impact of c-Myc expression and genetic alterations on
clinical outcomes (PFS and OS).

Extent of disease was evaluated according to the
Response Evaluation Criteria in Solid Tumors version 1.1
at screening, after every cycle for the first 6 months, and
subsequently every two cycles (between days 21 and
28) to assess disease response and progression; because
of the aggressiveness of SCLC, disease assessments were
performed more frequently than in common clinical
practice. Radiographic images (by contrast-enhanced
computed tomography or magnetic resonance imaging)
were assessed locally and submitted for central review if
the results were positive. For biomarker evaluations, c-
Myc expression was assessed by immunohistochemical
analysis of c-Myc expression in tumor tissue, and genetic
alterations were assessed retrospectively by next-
generation sequencing (NGS) of circulating tumor DNA
(ctDNA) from peripheral blood by using a custom
PlasmaSelect-R (Personal Genome Diagnostics, Inc., Bal-
timore, MD) targeted gene NGS panel (Supplementary
Table 1).

Details of follow-up for PFS and OS, and the methods
used for the biomarker assessments, are provided in the
Supplementary Methods. Toxicity was graded according
to the National Cancer Institute Common Terminology
Criteria for Adverse Events version 4.03. The use of
myeloid growth factors for the management of neu-
tropenia was not mandated but was permitted at the
discretion of the investigator if clinically indicated, ac-
cording to local guidelines and the product label.

**Statistical Analysis**

The intent-to-treat (ITT) population included all
randomized patients and was used for the primary
analysis of PFS and all secondary efficacy end points. The
safety population included all patients who received at
least one dose of any study drug.

Full statistical methods are provided in the
Supplementary Methods. Assuming a median PFS of 3
months for the placebo plus paclitaxel (henceforth
referred to as placebo/paclitaxel) arm and also assuming
that alisertib/paclitaxel could improve median PFS to 5
months (40% reduction of hazard), a minimum of 138
PFS events were required for the primary analysis (two-
sided alpha 0.05, power 85%). PFS was tested by using a
two-sided stratified log-rank test to compare arms.
Hazard ratios (HRs) and 95% confidence intervals (CI)
were estimated by using a Cox proportional hazard
regression model stratified by type of relapse and
presence of brain metastases, with treatment arm
included as a factor in the model. Kaplan-Meier survival
curves were provided for each arm. OS and other time-
to-event end points were analyzed by using similar
methods.

Assessment of c-Myc expression by immunohisto-
chemistry was analyzed as (1) percentage of positive
cells or (2) dichotomized readout converted to a binary
variable (positive versus negative) based on modal in-
tensity. For both methods, a Cox proportional hazard
model was used to analyze PFS, with treatment and c-
Myc expression as the main effects. Interactions between
NGS-identified genetic alterations and treatments (ali-
sertib versus placebo) were tested with a Cox propor-
tional hazards model for PFS and OS. The genetic
alterations tested included single-gene mutations
(mutant allele frequency ≥0.01), pathway gene muta-
tions, and mutation load.

A protocol amendment (January 2015) corrected the
stratification definition of relapse type after primary
treatment so that relapses were recorded “from last
administration of platinum-based chemotherapy” rather
than “from initial response.” To maintain balance, the
primary end point was analyzed by using the original
stratification definition of relapse type. However, a
sensitivity analysis with use of the corrected stratifica-
tion definition was also included.

**Results**

**Patients**

A total of 178 patients were enrolled and randomized
to receive alisertib/paclitaxel (n = 89) or placebo/
paclitaxel (n = 89 [Supplementary Fig. 1]). Patient
characteristics at baseline are shown in Table 1. Two
patients in the alisertib/paclitaxel arm were randomized
but did not receive any study drug and were included in
the ITT population analysis only. When the corrected
definition of relapse type (sensitive versus resistant or
refractory disease) was used, 53 (30%) patients had
their relapse stratification factor changed after initial classification, and there was a higher ratio of percentage of sensitive patients in the placebo/paclitaxel arm to that in the alisertib/paclitaxel arm (42:33) compared with when the original definition (45:40) was used (see Table 1). In addition, for five patients in the placebo/paclitaxel arm who had been enrolled under the original definition, sufficient data had not been provided to allow classification under the corrected definition, so they were excluded from the corrected stratification analysis.

**Efficacy**

The median PFS was 3.32 months in the alisertib/paclitaxel arm versus 2.17 months in the placebo/paclitaxel arm (HR = 0.77, 95% CI: 0.557–1.067, p = 0.113). In the prespecified sensitivity analysis, when the corrected definition for the stratification factor of relapse type was used, the HR was 0.71 (95% CI: 0.509–0.985, p = 0.038; [Fig. 1A]). There were no differences in PFS between arms based on the presence of metastases, enrollment region, Eastern Cooperative Oncology Group performance status, age category, race, or disease stage (data not shown). Although there was no difference in PFS for male patients (HR = 1.03, 95% CI: 0.677–1.578, p = 0.876), there was a marginal difference for female patients in favor of alisertib/paclitaxel compared with placebo/paclitaxel (median PFS 4.4 versus 2.6 months [HR = 0.60, 95% CI: 0.367–0.992, p = 0.043]). For patients with resistant or refractory relapse (corrected definition), the median PFS was 2.86 months with alisertib/paclitaxel versus 1.68 months with placebo/paclitaxel (HR = 0.66, p = 0.037 [Fig. 1B]). For patients with sensitive relapse (corrected definition), the median PFS was 3.72 months with alisertib/paclitaxel versus 3.34 months with placebo/paclitaxel, respectively (HR = 0.86, 95% CI: 0.493–1.497, p = 0.590).

At data cutoff, there was no significant difference in OS between arms (Fig. 1C). The median OS was 6.11 months with alisertib/paclitaxel versus 5.42 months with placebo/paclitaxel. Per protocol, a further OS

### Table 1. Demographics and Baseline Disease Characteristics (Intent-to-Treat Population)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Alisertib/Paclitaxel (n = 89)</th>
<th>Placebo/Paclitaxel (n = 89)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age, y (range)</td>
<td>62 (37-81)</td>
<td>62 (46-86)</td>
</tr>
<tr>
<td>Male sex, n (%)</td>
<td>51 (57)</td>
<td>50 (56)</td>
</tr>
<tr>
<td>Median time since initial diagnosis, mo (range)</td>
<td>7.4 (3-12)</td>
<td>7.8 (3-26)</td>
</tr>
<tr>
<td>VALG stage at initial diagnosis, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Limited</td>
<td>18 (20)</td>
<td>8 (9)</td>
</tr>
<tr>
<td>Extensive</td>
<td>61 (69)</td>
<td>62 (70)</td>
</tr>
<tr>
<td>Unknown</td>
<td>10 (11)</td>
<td>19 (21)</td>
</tr>
<tr>
<td>ECOG PS, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>27 (30)</td>
<td>18 (20)</td>
</tr>
<tr>
<td>1</td>
<td>62 (70)</td>
<td>71 (80)</td>
</tr>
<tr>
<td>Smoking history, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>4 (4)</td>
<td>7 (8)</td>
</tr>
<tr>
<td>Former/current</td>
<td>52 (58)/33 (37)</td>
<td>52 (59)/29 (33)</td>
</tr>
<tr>
<td>Missing</td>
<td>0</td>
<td>1 (1)</td>
</tr>
<tr>
<td>No prior prophylactic cranial irradiation, n (%)</td>
<td>59 (66)</td>
<td>63 (71)</td>
</tr>
<tr>
<td>No brain involvement at baseline, n (%)</td>
<td>62 (70)</td>
<td>63 (71)</td>
</tr>
<tr>
<td>Type of relapse after primary treatment (by IVRS), n (%)</td>
<td>36 (40)</td>
<td>40 (45)</td>
</tr>
<tr>
<td>Sensitive</td>
<td>36 (40)/17 (19)</td>
<td>34 (38)/15 (17)</td>
</tr>
<tr>
<td>Resistant/refractory</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type of relapse after primary treatment (corrected), n (%)</td>
<td>29 (33)</td>
<td>35 (42)</td>
</tr>
<tr>
<td>Sensitive</td>
<td>41 (46)/19 (21)</td>
<td>33 (39)/16 (19)</td>
</tr>
<tr>
<td>Resistant/refractory</td>
<td>0</td>
<td>5 (6)</td>
</tr>
<tr>
<td>Not classifiable or missing</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*pMissing data were treated as missing and no data imputation was applied.

*Sensitive disease is defined as progression of disease observed >90 days from the last dose of first-line platinum-based chemotherapy, resistant disease is defined as progression of disease observed <90 days after first-line platinum-based chemotherapy, and refractory disease is defined as no objective response and progression either during or immediately after first-line platinum-based chemotherapy.

Protocol Amendment 2 (January 2015) corrected the stratification definition for time to relapse to follow standard guidance by counting from date of last dose of frontline chemotherapy as opposed to by counting from initial response to first-line platinum-based chemotherapy, as originally set out in the protocol; the stratification factors for the study were corrected accordingly. When the corrected definition of time to relapse for type of relapse after primary treatment (sensitive versus resistant or refractory disease) was used, 53 patients (30%) had their relapse stratification factor changed after initial classification. In all, 15 patients in the alisertib plus paclitaxel arm and 14 in the placebo plus paclitaxel arm were reassigned from “sensitive” to “resistant or refractory” relapse, and 8 and 11 patients, respectively, were reassigned from “resistant or refractory” to “sensitive” relapse.

ECOG PS, Eastern Cooperative Oncology Group performance status; IVRS, Interactive Voice Response System; VALG, Veterans Administration Lung Study Group.
analysis, including data from at least 80% of patients, was conducted on October 15, 2016. Overall, 151 patients had died at this time, which was an increase of 23 deaths from the previous analysis. The updated median OS was 6.86 months with alisertib/paclitaxel versus 5.58 months with placebo/paclitaxel (HR = 0.93, 95% CI: 0.652–1.341, \( p = 0.714 \); HR with use of the corrected definition for relapse type = 0.73, 95% CI: 0.520–1.021, \( p = 0.064 \)).

The ORR was 22% with alisertib/paclitaxel versus 18% with placebo/paclitaxel (Table 2). The DCR was 58% versus 46%, respectively. For the subgroup of resistant or refractory patients when the corrected definition for relapse type was used, the DCR was significantly higher with alisertib/paclitaxel than with placebo/paclitaxel (55% versus 33% [odds ratio = 0.40 (range 0.18–0.87), \( p = 0.020 \)]. The median DOR among responders was 3.16 months in the alisertib/paclitaxel arm and 2.79 months in the placebo/paclitaxel arm (see Table 2). The median time to progression was 3.58 months with alisertib/paclitaxel versus 2.60 months with placebo/paclitaxel (HR = 0.67, \( p = 0.038 \)) (see Table 2).

### Exploratory Correlative Biomarker Studies

In all, 46 tumor tissue samples were evaluable for the c-Myc expression by immunohistochemistry analysis; 33 (72%) were positive (a modal intensity of 1+, 2+, or 3+) for c-Myc expression and 13 (28%) were negative (modal intensity = 0). PFS by c-Myc expression is shown in Fig. 1D and 1E. In c-Myc–positive patients, the median PFS was 4.64 months with alisertib/paclitaxel (\( n = 17 \)) versus 2.27 months with placebo/paclitaxel (\( n = 16 \)) (HR = 0.29, 95% CI: 0.12–0.72). In c-Myc–negative patients, the median PFS was 3.32 months with alisertib/paclitaxel (\( n = 6 \)) versus 5.16 months with placebo/paclitaxel (\( n = 7 \)) (HR = 11.8, 95% CI: 1.52–91.2). c-Myc expression was strongly associated with improved PFS when c-Myc was evaluated as a continuous variable of percentage of cells staining positive (\( p_{\text{continuous}} = 0.0045 \)) or a binary (positive versus negative) mode (\( p_{\text{binary}} = 0.0006 \)).

Out of 176 patients, 155 (88%) provided plasma samples that were processed for NGS analysis of ctDNA. In all, 142 patient samples (81%) were successfully sequenced and genetic alterations were identified from 140 patients (80%) (Supplementary Fig. 1). The full

**Figure 1.** Clinical outcomes for the intent-to-treat population and according to resistant or refractory relapse and c-Myc expression. (A) Progression-free survival (PFS) in all patients. (B) PFS in patients with resistant or refractory relapse. (C) Overall survival in all patients. (D) PFS in patients positive for c-Myc expression. (E) PFS in patients negative for c-Myc expression. (A–C) Hazard ratios (HRs), 95% confidence intervals (CIs), and \( p \) values for the comparison of alisertib plus paclitaxel versus placebo plus paclitaxel are shown per protocol and with use of the corrected definition for the stratification factor of relapse type.
results from this genetic profiling are provided in the Supplementary Results (Supplementary Figs. 2–6 and see also Supplementary Fig. 1). The genetic mutation profiles revealed from the SCLC plasma ctDNA samples were concordant with those previously identified in SCLC primary tumor tissue,24 matching the mutational frequency trends in characterized genes, such as tumor protein p53 gene (TP53), retinoblastoma gene (RB1), formin 2 gene (FMN2), notch receptor 1 gene (NOTCH1), collagen type XXII alpha 1 chain gene (COL22A1), spectrin repeat containing nuclear envelope protein 1 gene (SYNE1), CREB binding protein gene (CREBBP), ATRX chromatin remodeler gene (ATRX), notch receptor 3 gene (NOTCH3), regulating synaptic membrane exocytosis 2 gene (RIMS2), and contactin associated protein-like 2 gene (CNTNAP2) (Fig. 2A). The mutation spectrum of the key genes also showed high concordance (see Supplementary Fig. 3). The correlative analysis of clinical outcomes (PFS and OS) was assessed in relation to (1) individual gene mutations, (2) biological pathway gene mutations, and (3) overall mutation load.

At the individual gene mutation level, five of the mutated genes were found to have marginal significance to PFS or OS in the alisertib/paclitaxel arm: RBL1, adenylate cyclase 1 gene (ADCY1), CNTNAP2, zinc finger protein 217 gene (ZNF217), and BCL2 associated transcription factor 1 gene (BCLAF1) (Fig. 2B). When grouped by biological pathway (see Supplementary Figs. 4 and 5), mutations in genes involved in cell cycle regulation (cyclin-dependent kinase 6 gene [CDK6], retinoblastoma-like 1 gene [RBL1], retinoblastoma-like 2 gene [RBL2], and retinoblastoma 1 gene [RB1]) were significantly associated with improved PFS (p = 0.0011) and OS (p = 0.00096) after alisertib/paclitaxel treatment. No such association was shown for mutated genes involved in NOTCH (NOTCH1, NOTCH2, and NOTCH3) or phosphoinositide 3-kinase (KIT proto-oncogene receptor tyrosine kinase gene [KIT], phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene [PIK3CA], phosphatase and tensin homolog gene [PTEN], tumor protein p73 gene [TP73]) signaling, or histone modifications (CREBBP and E1A binding protein p300 gene [EP300]) (see Supplementary Fig. 5). Patients with mutations in cell cycle regulators (“mutant”) had improved median PFS (3.68 versus 1.80 months [HR = 0.395, 95% CI: 0.239–0.654, p = 0.0003]) (Fig. 3A and 3B) and OS (7.20 versus 4.47 months [HR = 0.427, 95% CI: 0.259–0.704, p = 0.00085]) with alisertib/paclitaxel (n = 40) compared with placebo/paclitaxel (n = 47) (Fig. 3C and 3D). Conversely, patients without mutations in cell cycle regulators (“wild type”) had no improvement in median PFS (2.63 versus 2.60 months [HR = 1.31, 95% CI: 0.736–2.33, p = 0.359]) (see Fig. 3A and 3B) or OS (4.47 versus 5.95 months [HR = 1.70, 95% CI: 0.865–3.33, p = 0.124]) with alisertib/paclitaxel (n = 28) versus placebo/paclitaxel (n = 25) (see Fig. 3C and 3D). Across the 140 samples sequenced, 2151 mutations were identified, with a mean mutational load of 12.93 mutations per megabase pair of panel sequenced and a median value of 8.52 mutations per megabase pair (see Supplementary Fig. 6). Correlation between mutational load and PFS or OS in the alisertib arm was marginally significant for OS (p = 0.025) but not for PFS (p = 0.103). Notably, patient samples with mutations in cell cycle regulation genes had a significantly higher mutational load (a mean of 19.03) compared with those without cell cycle regulation gene mutations (a mean of 9.06) (p < 0.0001) (see Supplementary Fig. 6).

**Safety and Tolerability**

The median numbers of cycles received in the alisertib/paclitaxel and placebo/paclitaxel arms were 3

---

**Table 2. Best Overall Response Rate (ITT Population), Duration of Response, and Time to Progression**

<table>
<thead>
<tr>
<th>Variable, n (%)</th>
<th>Alisertib/Paclitaxel (n = 89)</th>
<th>Placebo/Paclitaxel (n = 89)</th>
<th>OR/HR (95% CI); p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Response, n (%)</td>
<td>ORR (CR + PR)</td>
<td>CR</td>
<td>PR</td>
</tr>
<tr>
<td>----------------</td>
<td>----------------</td>
<td>----</td>
<td>----</td>
</tr>
<tr>
<td>ORR (CR + PR)</td>
<td>0.74 (0.35–1.55); 0.046</td>
<td>0.0011</td>
<td>0.0003</td>
</tr>
<tr>
<td>CR</td>
<td>0.0011</td>
<td>0.0011</td>
<td>0.0011</td>
</tr>
<tr>
<td>PR</td>
<td>0.0003</td>
<td>0.0003</td>
<td>0.0003</td>
</tr>
<tr>
<td>Stable disease</td>
<td>0.00085</td>
<td>0.00085</td>
<td>0.00085</td>
</tr>
<tr>
<td>DCR (CR + PR + stable disease ≥8 weeks)</td>
<td>0.0003</td>
<td>0.0003</td>
<td>0.0003</td>
</tr>
<tr>
<td>PD</td>
<td>0.00085</td>
<td>0.00085</td>
<td>0.00085</td>
</tr>
<tr>
<td>No on-study imaging</td>
<td>0.0003</td>
<td>0.0003</td>
<td>0.0003</td>
</tr>
<tr>
<td>Median DOR (responders), mo (95% CI)</td>
<td>0.00085</td>
<td>0.00085</td>
<td>0.00085</td>
</tr>
<tr>
<td>Median TTP (ITT), mo (95% CI)</td>
<td>0.00085</td>
<td>0.00085</td>
<td>0.00085</td>
</tr>
</tbody>
</table>

*Missing data were treated as missing and no data imputation was applied.

Three patients died before on-study imaging, two patients were not assessed, and two patients were not dosed.

Four patients died before on-study imaging, one patient was not assessed, and one patient was too ill for imaging.

CI, confidence interval; CR, complete response; DCR, disease control rate; DOR, duration of response; HR, hazard ratio; ITT, intent-to-treat population; NE, not evaluated; OR, odds ratio; ORR, objective response rate; PD, disease progression; PR, partial response; TTP, time to progression.
Figure 2. Association between gene mutations and clinical outcomes. (A) Gene mutation frequencies identified in this study by using circulating tumor DNA (ctDNA) were compared with those reported previously in primary tumor tissue samples from patients with SCLC. Mutation frequencies for the 20 most commonly mutated genes are shown. (B) The interaction between genetic alterations and clinical outcomes (progression-free survival [PFS] and overall survival [OS]) was tested by using a Cox proportional hazards model. The \( p \) values and false discovery rates (FDRs) for the association with outcome are shown. Mutations in retinoblastoma 1 gene (\textit{RB1}), BCL associated transcription factor 1 gene (\textit{BCLAF1}), contactin associated protein-like 2 gene (\textit{CNTNAP2}), adenylate cyclase 1 gene (\textit{ADCY1}), and zinc finger protein 217 gene (\textit{ZNF217}) were independently associated with alisertib plus paclitaxel versus with placebo plus paclitaxel efficacy, as defined by hazard ratios for PFS and OS. Abbreviations: \textit{TP53}, tumor protein p53 gene; \textit{FMN2}, formin 2 gene; \textit{NOTCH1}, notch receptor 1 gene; \textit{COL22A1}, collagen type XXII alpha 1 chain gene; \textit{SYNE1}, spectrin repeat containing nuclear envelope protein 1 gene; \textit{ATRX}, ATRX chromatin remodeler gene; \textit{CREBBP}, CREB binding protein gene; \textit{ERICH3}, glutamate rich 3 gene; \textit{KIAA1211}, KIAA1211 gene (now known by the gene symbol \textit{CRACD}); \textit{TMEM132D}, transmembrane protein 132D gene; \textit{COL11A1}, collagen type XI alpha 1 chain gene; \textit{NOTCH3}, notch receptor 3 gene; \textit{SPHKAP}, SPHK1 interactor, AKAP domain containing gene; \textit{RIMS2}, regulating synaptic membrane exocytosis 2 gene; \textit{ZDBF2}, zinc finger DBF-type containing 2 gene; \textit{AR}, androgen receptor gene; \textit{CNTNAP2}, contactin associated protein 2 gene; \textit{EP300}, E1A binding protein p300 gene.
Diarrhea and fatigue were the most common adverse events (AEs); both were reported more frequently with alisertib/paclitaxel than with placebo/paclitaxel. Grade 3 or higher AEs were more common with alisertib/paclitaxel (76%) than with placebo/paclitaxel (51%), including the most common individual grade 3 or higher AE, neutropenia (Table 3). Drug-related AEs were also more common with alisertib/paclitaxel than with placebo/paclitaxel (see Table 3); the most common drug-related grade 3 or higher AEs were neutropenia, febrile neutropenia, leukopenia, anemia, diarrhea, and

![Figure 3](image-url)

**Figure 3.** Clinical outcomes according to treatment and mutations in cell cycle regulation pathway genes. (A) Cox proportional hazard regression analysis of progression-free survival (PFS) in patients with (mutant) and without (wild-type) mutations in cell cycle pathway genes, respectively. In each subgroup, the hazard ratio (HR) between the two treatment arms (alisertib plus paclitaxel versus placebo plus paclitaxel) was estimated, along with the 95% confidence interval (CI) and \( p \) value. (B) Kaplan-Meier plots of PFS in mutant and wild-type patients, respectively. The \( p \) value in this panel is the interaction effect between treatment group and mutation status and is calculated by testing the difference between the HRs for the two subgroups. (C) Cox proportional hazard regression analysis of overall survival (OS) in mutant and wild-type patients, respectively. In each subgroup, the HR between the two treatment arms (alisertib plus paclitaxel versus placebo plus paclitaxel) was estimated, along with the 95% CI and \( p \) value. (D) Kaplan-Meier plots of OS in mutant and wild-type patients, respectively. The \( p \) value in this panel is the interaction effect between treatment group and mutation status and is calculated by testing the difference between the HRs for the two subgroups.
stomatitis, which were all reported more frequently with alisertib/paclitaxel than with placebo/paclitaxel. Similarly, in the alisertib/paclitaxel arm, 38 patients (44%) reported a serious AE (SAE) and 28 (32%) reported a drug-related SAE, compared with 28 patients (31%) and six (7%), respectively, in the placebo/paclitaxel arm. The most common (≥5% of patients in either treatment arm) all-cause SAEs with alisertib/paclitaxel were febrile neutropenia (10%), neutropenia (6%), diarrhea (6%), and stomatitis (5%). There were no SAEs of febrile neutropenia, neutropenia, or diarrhea with placebo/paclitaxel; one patient (1%) reported an SAE of stomatitis.

In the alisertib/paclitaxel and placebo/paclitaxel arms, 14 patients (16%) and five (6%) discontinued study treatment because of an AE, 33 patients (38%) and nine (10%) had a dose reduction because of an AE, and 12 patients (14%) and 11 (12%) died during the study (within 30 days of last dose). Four of these deaths, all in the alisertib/paclitaxel arm, were assessed as drug related, including one each due to neutropenic sepsis, sepsis, febrile neutropenia, and septic shock (see Table 3).

| Table 3. Most Frequently Reported All-Cause and Drug-Related Treatment-Emergent AEs, Occurring in at Least 15% (All-Cause) or at Least 10% (Drug-Related) of Patients Overall (Any Grade) in Either Arm, Respectively, with the Corresponding Grade 3 or higher AEs (Safety Population), and All Drug-Related Fatal AEs |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| AE              | Alisertib/Paclitaxel (n = 87) | Placebo/Paclitaxel (n = 89) |
|                 | Any Grade       | Grade ≥3        | Any Grade       | Grade ≥3        |
| All-cause AE,  n (%) | 86 (99)         | 66 (76)         | 85 (96)         | 45 (51)         |
| Diarrhea        | 51 (59)         | 14 (16)         | 18 (20)         | 1 (1)           |
| Fatigue         | 38 (44)         | 9 (10)          | 29 (33)         | 5 (6)           |
| Nausea          | 29 (33)         | 2 (2)           | 30 (34)         | 4 (4)           |
| Anemia          | 38 (44)         | 12 (14)         | 18 (20)         | 3 (3)           |
| Neutropenia     | 43 (49)         | 35 (40)         | 7 (8)           | 5 (6)           |
| Vomiting        | 28 (32)         | 2 (2)           | 21 (24)         | 3 (3)           |
| Decreased appetite | 29 (33)       | 3 (3)           | 19 (21)         | 3 (3)           |
| Dyspnea         | 21 (24)         | 4 (5)           | 19 (21)         | 2 (2)           |
| Stomatitis      | 29 (33)         | 12 (14)         | 6 (7)           | 2 (2)           |
| Cough           | 17 (20)         | 0               | 17 (19)         | 0               |
| Constipation    | 8 (9)           | 1 (1)           | 21 (24)         | 0               |
| Anemia          | 14 (16)         | 3 (3)           | 11 (12)         | 0               |
| Nausea          | 14 (16)         | 0               | 8 (9)           | 0               |
| Alopecia        | 14 (16)         | 0               | 5 (6)           | 0               |
| Leukopenia      | 13 (15)         | 7 (8)           | 5 (6)           | 2 (2)           |
| Decreased neutrophil count | 14 (16) | 11 (13) | 4 (4) | 1 (1) |
| Weight decreased | 13 (15)         | 0               | 5 (6)           | 0               |
| Drug-related AE, n (%) | 81 (93)       | 58 (67)         | 72 (81)         | 22 (25)         |
| Diarrhea        | 44 (51)         | 13 (15)         | 11 (12)         | 1 (1)           |
| Fatigue         | 32 (37)         | 7 (8)           | 23 (26)         | 3 (3)           |
| Nausea          | 24 (28)         | 2 (2)           | 26 (29)         | 4 (4)           |
| Neutropenia     | 41 (47)         | 33 (38)         | 7 (8)           | 5 (6)           |
| Anemia          | 31 (36)         | 9 (10)          | 14 (16)         | 1 (1)           |
| Vomiting        | 23 (26)         | 2 (2)           | 14 (16)         | 2 (2)           |
| Stomatitis      | 28 (32)         | 11 (13)         | 6 (7)           | 2 (2)           |
| Decreased appetite | 21 (24)         | 3 (3)           | 13 (15)         | 1 (1)           |
| Leukopenia      | 13 (15)         | 7 (8)           | 5 (6)           | 2 (2)           |
| Alopecia        | 12 (14)         | 0               | 5 (6)           | 0               |
| Neutrophil count decreased | 13 (15) | 10 (11) | 4 (4) | 1 (1) |
| Febrile neutropenia | 11 (13) | 11 (13) | 0 | 0 |
| WBC count decreased | 11 (13) | 11 (13) | 1 (1) | 1 (1) |
| Asthenia        | 9 (10)          | 3 (3)           | 6 (7)           | 0               |
| Drug-related fatal AE, n (%) | — | — | — | 0 |
| Neutropenic sepsis | — | 1 (1) | — | 0 |
| Sepsis          | — | 1 (1) | — | 0 |
| Febrile neutropenia | — | 1 (1) | — | 0 |
| Septic shock    | — | 1 (1) | — | 0 |

AE, adverse event; WBC, white blood cell.
Discussion

In this study of alisertib/paclitaxel versus placebo/paclitaxel as second-line therapy in patients with advanced SCLC, the primary end point of PFS in the ITT population was not met, but PFS was significantly improved when analyzed on the basis of the corrected definition of relapse type after first-line therapy (as intended by the protocol), with a positive trend favoring alisertib/paclitaxel ($p = 0.038$). However, this PFS benefit was not clinically meaningful. Similarly, the subgroup analysis of type of relapse after first-line therapy (corrected definition) demonstrated a statistically significant improvement in PFS with alisertib/paclitaxel over that with placebo/paclitaxel in patients with resistant or refractory relapsed SCLC ($p = 0.037$). However, the primary analysis of PFS conducted by using the original stratification definition of relapse type was not significant on statistical testing. Despite a trend in favor of alisertib/paclitaxel, there was no significant difference in OS between arms; however, the study was not powered to show an OS advantage. Notably, the correlative biomarker studies indicated that both c-Myc expression and mutations in cell cycle regulators (CDK6, RBL1, RBL2, and RB1) showed strong correlation with improved clinical outcomes (PFS and OS) in patients with SCLC who were receiving alisertib/paclitaxel. These findings are consistent with the mechanism of action of alisertib as a mitotic inhibitor disrupting cell cycle progression through mitosis. Thus, c-Myc expression or cell cycle gene mutations may serve as predictive biomarkers for alisertib.

When the results are interpreted, there are points to consider. Although not the primary end point, the sensitivity analysis of PFS using the corrected definition of relapse type may represent a more clinically relevant, scientifically valid approach. In the PFS sensitivity analysis with use of the corrected definition of relapse type, patients without a stratification factor were excluded, improving internal validity. There was also a higher ratio of sensitive patients in the placebo/paclitaxel arm to sensitive patients in the alisertib/paclitaxel arm (42:33), as compared with when the original definition was used (45:40); therefore, the original analysis favored placebo/paclitaxel. Finally, doses of paclitaxel were different in each arm to account for the pharmacodynamic synergy of paclitaxel with alisertib.

The median PFS with placebo/paclitaxel was slightly shorter than in a previous study of second-line paclitaxel monotherapy in patients with SCLC (4.76 months), whereas the median OS was in line with values in previous reports (3.3–5.8 months). A longer interval between restaging scans could lead to overestimation of PFS, and the shorter PFS duration in our study potentially reflects the more rigorous restaging scan schedule (every 4 weeks for the first six cycles), which enabled more accurate estimation of PFS than in previous studies.

Although cross-trial comparison should be approached with caution, the response rate of 22% observed with the alisertib/paclitaxel combination in the study is comparable to the 21% response rate associated with single-agent alisertib in 48 patients with SCLC in a phase 1/2 study, which may suggest that synergy of the combination is limited in this treatment setting.

Because of the overlapping toxicity profile for alisertib and paclitaxel, there was a higher incidence of grade 3 or higher AEs and drug-related AEs with this combination versus with paclitaxel alone. Increased toxicity is a concern in this treatment setting, in which many patients are not clinically robust. Clinically manageable hematologic events were among the most frequent drug-related grade 3 or higher treatment-emergent AEs in patients who received alisertib/paclitaxel; of particular note, a high rate of grade 3 or higher neutropenia (38%) was observed. Overall, 44 patients in the study received myeloid growth factor support to manage neutropenia (34 patients in the alisertib/paclitaxel arm and 10 patients in the placebo/paclitaxel arm). Rates of on-study deaths were similar in both arms, but four AE-related deaths (due to febrile neutropenia, neutropenic sepsis, sepsis, and septic shock) occurred only with alisertib/paclitaxel.

AAK binds to c-Myc and prevents its degradation, thereby enhancing its growth-promoting effect in cancer cells. Conversely, pharmacologic inhibition of AAK in preclinical studies results in greater growth inhibition in cell lines harboring MYC amplification. We therefore anticipated that patients whose tumors harbored high c-Myc expression would be susceptible to an AAK inhibitor (as seen in preclinical studies). Moreover, as c-Myc alteration may be correlated with poor response to chemotherapy, we anticipated that patients with resistant or refractory relapse would derive greater benefit. Consistent with this hypothesis, alisertib/paclitaxel showed significant benefit over placebo/paclitaxel in patients with resistant or refractory relapse and in patients with c-Myc expression. Although the numbers were low and the results need to be reproduced in a larger independent study, we expect that enrichment strategies for these patient subsets could aid further development of alisertib in SCLC.

With respect to genetic biomarkers, patients treated with alisertib/paclitaxel who had mutations in cell cycle regulator genes, including CDK6, RBL1, RBL2, and RB1, had significantly improved PFS and OS compared with those who received placebo/paclitaxel. Previous genomic landscape studies have implicated cell cycle...
regulation genes as being commonly mutated in SCLC.\(^\text{24,29}\) Our findings suggest a predictive value of these mutations with alisertib/paclitaxel treatment for SCLC. Interestingly, patients with mutated cell cycle regulators had worse outcomes in response to placebo/paclitaxel treatment; the implications of these findings warrant further investigation. Our study results are consistent with, and provide validation, of the findings from two preclinical reports in *Cancer Discovery*, which describe a synthetic lethal relationship between *RB1* mutations and inhibition of AAK or Aurora B kinase.\(^\text{30,31}\) The predictive value of cell cycle mutations for alisertib treatment in other diseases is also of interest and worth further exploration. Importantly, our data highlight the emerging role of NGS profiling of plasma ctDNA for identifying novel predictive biomarkers.

No predictive value was demonstrated in genetic alterations in other cell cycle progression genes implicated in SCLC, such as amplification of Aurora kinase A gene (*AURKA*) and *MYC*\(^\text{10,17,32,33}\) (data not shown). Similarly, pathway mutations in genes implicated in NOTCH and phosphoinositide 3-kinase signaling, and histone modifications, showed no association with PFS or OS in response to alisertib treatment. As these parameters were established retrospectively, the study was not optimized for this metric.

A key limitation of our study was the failure to use a validated biomarker for prospective patient selection. Although post hoc biomarker interrogation supported c-Myc expression and mutations in cell cycle regulator genes as promising biomarkers, these observations require more rigorous prospective testing and validation. Additionally, the study failed to demonstrate survival benefit of alisertib/paclitaxel compared with placebo/paclitaxel. Patients entering this study were stratified by platinum sensitivity status based on data available at the time, which suggested that platinum sensitivity status was correlated with efficacy outcomes. However, data from studies in relapsed SCLC published during the conduct of this trial suggest that platinum sensitivity may not be strongly associated with efficacy outcomes and that other prognostic subgroups could be more relevant in study designs.\(^\text{34}\) Another limitation was that the comparator arm in this study was placebo/paclitaxel. At the time of this study’s design, topotecan was the only agent approved in the relapsed setting by the U.S. Food and Drug Administration (FDA),\(^\text{6,35}\) having demonstrated symptom reduction and less hematologic toxicity than with cyclophosphamide, doxorubicin, and vincristine,\(^\text{36}\) and survival benefit over best supportive care.\(^\text{37}\) Single-agent paclitaxel is frequently used off-label as a standard treatment for relapsed SCLC, and paclitaxel was chosen as the comparator in this study, rather than topotecan, because of the higher toxicity associated with topotecan, particularly the overlapping toxicity of neutropenia with alisertib, and the existence of preclinical and clinical data for the alisertib/paclitaxel combination.\(^\text{39}\) Recently, other agents have shown similar or improved efficacy compared with topotecan, including amrubicin\(^\text{8}\) and cisplatin, etoposide, and irinotecan,\(^\text{40}\) and in August 2018, nivolumab received accelerated approval by the FDA for patients with metastatic SCLC with progression after platinum-based chemotherapy and at least one other line of therapy.\(^\text{39}\) Approval was based on findings from the open-label, multicohort CHECKMATE-032 study (NCT01928394), which reported an ORR of 12% (95% CI: 6.5–19.5) in 109 patients (~65% with platinum-sensitive SCLC, defined as progression ≥90 days after the last dose of platinum-containing therapy), with 77% having a DOR of at least 6 months when treated with nivolumab with or without ipilimumab.\(^\text{39}\) Further treatment options continue to emerge for SCLC, including immunotherapy; in 2019, FDA approvals for have been granted for pembrolizumab in relapsed or refractory SCLC, based on the results of the KEYNOTE-028 (NCT02054806) and KEYNOTE-158 (NCT02628067) studies,\(^\text{40,41}\) and for atezolizumab in combination with chemotherapy in the frontline treatment of extensive-stage SCLC, based on the IMPower133 trial (NCT02763579).\(^\text{42}\) There were seven patients who had received treatment with immunotherapy before starting our study (two in the alisertib/paclitaxel arm and five in the placebo/paclitaxel arm); postprogression treatment information was not collected. Despite the emerging range of treatment options, topotecan remains the standard therapy in the second-line setting. Whether the efficacy signal observed in the present study is sufficient to support a definitive superiority trial in comparison with topotecan in unselected patients is difficult to ascertain, particularly in light of the negative result of the phase II trial of cabazitaxel versus topotecan in a similar population of patients with relapsed SCLC.\(^\text{7}\) However, a biomarker-enrichment strategy using c-Myc expression or mutations in cell cycle regulator genes could enhance the likelihood of success of such a comparative study.

In conclusion, alisertib/paclitaxel showed a modest efficacy signal as second-line therapy for SCLC. Because of the overlapping safety profile for alisertib and paclitaxel, grade 3 or higher AEs and drug-related AEs were more frequent with the combination than with paclitaxel alone. The predictive value of c-Myc expression and cell cycle gene mutations for AAK inhibitor susceptibility is promising, but prospective testing and validation are required. These results, along with those from a previous phase II study demonstrating activity of alisertib
monotherapy in patients with relapsed or refractory SCLC,\textsuperscript{23} may warrant further testing in a larger study with predictive biomarker enrichment strategy.

**Acknowledgments**

The study was funded by Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Employees participated in trial design, data review, analysis and interpretation, and article writing. All authors had full access to all the data on request and the lead authors had final responsibility for the decision to submit for publication. The authors would like to acknowledge all the patients who participated in these studies and their families, as well as all the investigators and site staff who made these studies possible. They would also like to thank the members of the independent data monitoring committee. The authors also acknowledge Erin Zagalov (Millennium Pharmaceuticals, Inc., Cambridge, MA) for reviewing the article and revising it critically for important intellectual content. Finally, the authors acknowledge writing support from Helen Johns of Fire-Kite, an Ashfield company, part of UDG Healthcare plc, during the development of this article, which was funded by Millennium Pharmaceuticals, Inc., and editorial support from Marcel Kuttab, PharmD (Millennium Pharmaceuticals, Inc.) in compliance with Good Publication Practice 3 ethical guidelines (Battisti WP, Baltzer L, Bridges D, et al., Good publication practice for community company–sponsored medical research: GPP3. *Ann Intern Med.* 2015;163:461–464). Takeda makes patient-level, de-identified data sets, and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda’s data sharing policy (see https://www.takedaclinicaltrials.com/ for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor’s qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

**Supplementary Data**

Note: To access the supplementary material accompanying this article, visit the online version of the Journal of Thoracic Oncology at www.jto.org and at https://doi.org/10.1016/j.jtho.2019.10.013.

**References**

16. Brockmann M, Poon E, Berry T, et al. Small molecule inhibitors of aurora-a induce proteasomal degradation of


